Chemotherapy Could Harm Or Kill You If You Have This Genetic Finding
Chemotherapy has been used for decades to treat patients with cancer. One common type of chemotherapy - called fluorouracil (5-FU) when given by IV, or capecitabine (Xeloda or CAPE) when given by pill – can be toxic or fatal to a small percentage of people who carry a genetic change in a gene called DPYD. The prevalence of this genetic finding varies in different populations. Data suggest that for people who carry one DPYD variant, 2-3% will die of a treatment-related fatality if they take one of these medications (25x higher than the risk of an average person receiving the same drugs at an average dose).
Why? We all carry 2 copies of a gene called DPYD that makes a chemical (DPD) that helps our bodies break down and get rid of these drugs after our body uses them. This process helps prevent the patient from developing toxic or fatal side effects from this chemo. But, up to 8% of people carry one variant in this gene that causes a partial deficiency of DPD. This can double their exposure to the toxic effects of these medications at standard doses. Two in 1000 patients carry two variants that result in a complete absence of DPD function – in such patients, exposure to 5-FU is often fatal.
If a patient develops toxicity to 5-FU or capecitabine, and it is recognized immediately, an antidote called uridine triacetate can be administered (at a total cost of >$180,000 USD for medication and care). But this process must occur quickly, so patients experiencing severe side effects must contact their providers without delay. An example used to illustrate such side effects is that of “an active and independent patient who starts a planned 14-day cycle of capecitabine and cannot walk to the bathroom independently by day 10.” Patients who have two variants in the gene will likely be much sicker, much faster.
Drug authorities in the UK and European Union have recommended pre-treatment DPYD testing since 2020. If patients there carry one copy of the variant (genetically intermediate metabolizers of the drug), they are first given half of the standard dose to see how they do. If the patients do okay when they take the drug, doctors can raise the dose. If the patient carry two variants in the gene (a complete absence of DPD), other drugs are recommended instead if possible, or a quarter of the usual starting dose is used.
Only recently the United States FDA issued warnings about this issue. In 2024, the agency issued a statement that physicians should “consider testing” before prescribing 5-FU and capecitabine and “must inform patient of availability of DPYD testing and the implications of testing.” The FDA stopped short of recommending that clinicians order genetic testing for DPYD on their patients before prescribing 5-FU or capecitabine. These rather loose recommendations, and the fact that highly influential cancer organizations have not supported testing have contributed to the problem. Only 3% of oncologists in the United States order such testing before giving patients these drugs. Implementing pre-treatment DPYD genetic testing can be challenging, but some major healthcare systems have done so successfully. Most U.S. insurers, both private and public, will cover genetic testing for DPYD (which typically costs less than $450), and studies have shown that this testing is cost-effective.
Different gene variants are found in people from various ethnic backgrounds. A Canadian physician, Dr. Anil Kapoor, who was diagnosed with colon cancer and tested negative for four common DPYDvariants died after one dose of 5-FU. Why? Those four common variants are found most often in people of European ancestry and Dr. Kapoor was of South Asian ancestry. Testing performed after his death showed that Dr. Kapoor indeed carried another variant in this gene. The Association of Molecular Pathology (AMP) recently published guidelines for which DPYD variants should be included on panels before these drugs are administered to ensure that tests better account for ethnic diversity.
· Genetic testing is changing rapidly. Most clinicians cannot keep up with the genetic factors that play into drug reactions (a specialty called pharmacogenetics) in addition to their own areas of work.
o Pharmacists and certified genetic counselors who specialize in this area can help. But, remarkably, these graduate-level health care professionals are not recognized as ‘healthcare providers’ by Medicare and Medicaid, and therefore many insurance companies. Without this recognition by our federal government it is difficult for these providers to get reimbursed for their services. Therefore, they are not utilized in patient care as often as they could and should be. However, “the downstream cost benefits (fewer adverse events, fewer hospitalizations, decreased length of stay in the hospital, patient satisfaction, etc.) can easily outweigh the cost of having a dedicated full-time employee” to support such services, explains Jai Patel, PharmD, CPP, Director, Cancer Pharmacology & Pharmacogenomics at Atrium Health Levine Cancer Institute in Charlotte, NC.
o In addition to offering DPYD testing, genetic panels are available that can help assess patients’ risk for adverse reactions to other chemotherapies and medications, such as those used to treat pain, depression, nausea, and acid-reflux. While many people experience these conditions, they are even more common in people with cancer. Therefore, pharmacogenetic testing may be very helpful in guiding the selection or dosing of other medications, with one study showing that the use of such panels in cancer care reduced adverse events by more than 50%.
o Some clinicians fear that genetic testing will delay treatment or feel that they can manage the symptoms if they occur, and do not wish to give lower doses of these medications. However, there are now data to suggest that lowering doses in these patients does not have a negative impact on their survival.
o Interpreting genetic testing panels can be challenging. Some clinicians fear that if they order this testing, they are responsible for interpreting the results and using it correctly, and worry that this creates liability for them and their health system. But some health systems, like OSHU, have been sued because they didn’t offer this testing and a patient died.
Clinical decision support tools for pharmacogenetics are available. They help the clinician by providing guidance on when genetic testing should be used, and what drug or dose to use to maximize safety and effectiveness. Kristine Ashcraft, President and Founder of YouScript, has devoted the last two decades to creating such tools. “Most providers have little exposure to genetics in their medical training and are understandably fearful of incorporating something they don’t understand into clinical decision-making. But when provided with tools to guide them, the majority of healthcare providers say this becomes easy to navigate.“
But many health systems don’t use these tools, or the tools are not easily and readily available in electronic medical records (EMR), or pharmacy systems. One pharmacist spent a year building his own digital tools in the EMR called Epic. Those tools will only help his health system and will require updates as the field changes. Many of the large multi-billion dollar EMR companies make it difficult for smaller companies to integrate their own digital tools, often requiring expensive and time-consuming hospital-by-hospital integration and charging hefty fees to be included in their networks. The FDA and our federal government should examine these power structures and how they influence the everyday practice of medicine.
International Conference on Genetics and Genomics of Diseases
Award Nomination: genetics-conferences.healthcarek.com/award-nomination/?ecategory=Awards&rcategory=Awardee
Award registration: genetics-conferences.healthcarek.com/award-registration/
For Enquiries: genetics@healthcarek.com
Get Connected Here
---------------------------------
---------------------------------
Comments
Post a Comment